TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10367320

Group type: EXPERIMENTAL
Intervention: Avonex 6.0 MUI (30 micrograms) administered by intramuscular injection weekly
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 301
Study: 7747534

Group type: EXPERIMENTAL
Intervention: Miconazole-hydrocortisone cream and ketoconazole shampoo (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocortisone cream and placebo shampoo (Group B)
Number of subjects: 60
Study: 2157982

Group type: EXPERIMENTAL
Intervention: 33B3.1 (10 mg per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 33B3.1
Number of subjects: 100

Group type: COMPARATOR
Intervention: 33B3.1 and antithymocyte globulin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antithymocyte globulin
Number of subjects: 100
Study: 393377

Group type: EXPERIMENTAL
Intervention: Surgical treatment plus adjuvant therapy with DTIC and Corynebacterium parvum
Number of subjects: 61

Group type: COMPARATOR
Intervention: Surgical treatment only (control group)
Number of subjects: 61
Study: 30660472

Group type: EXPERIMENTAL
Intervention: MRI-based radiomics classifier using four post-T1WI-MRI radiomics features
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Radiomics classifier combined with clinical data
Number of subjects: 127

Group type: COMPARATOR
Intervention: Clinical risk model (Karnofsky performance status, radiation therapy)
Number of subjects: 127
Study: 26934834

Group type: EXPERIMENTAL
Intervention: Non-end-rounded brushes
Number of subjects: 46

Group type: COMPARATOR
Intervention: 40-50% end-rounded brushes
Number of subjects: 46

Group type: COMPARATOR
Intervention: >90% end-rounded brushes
Number of subjects: 46
Study: 25992877

Group type: EXPERIMENTAL
Intervention: Tight intraoperative glucose control with hyperinsulinemic-normoglycemic clamp (target blood glucose, 80 to 110 mg/dl)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard therapy (conventional insulin administration with blood glucose target, <150 mg/dl)
Number of subjects: 198
Study: 23351820

Group type: EXPERIMENTAL
Intervention: PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synchronous clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)
Number of subjects: 30
Study: 21995153

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta estradiol (HT group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 19476991

Group type: EXPERIMENTAL
Intervention: Nickel titanium archwires
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stainless steel archwires
Number of subjects: 20
Study: 17672263

Group type: EXPERIMENTAL
Intervention: EC 40
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cervitec
Number of subjects: 47

Group type: COMPARATOR
Intervention: ChemFil Varnish (control)
Number of subjects: 47
Study: 14726370

Group type: EXPERIMENTAL
Intervention: Follow up every three months
Number of subjects: 609

Group type: COMPARATOR
Intervention: Follow up every six months
Number of subjects: 609
Study: 11345371

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 516

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 516
Study: 8989011

Group type: EXPERIMENTAL
Intervention: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 7966066

Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intramuscular methotrexate (MTX)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined analysis with 15 patients already receiving DMARD treatment (n = 63)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with impaired functional capacity
Number of subjects: 48
Study: 3495259

Group type: EXPERIMENTAL
Intervention: Touristil (C+D)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cinnarizine 40 mg (C)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Domperidone 30 mg (D)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (pl)
Number of subjects: 25
Study: 29274242

Group type: EXPERIMENTAL
Intervention: Originator infliximab
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Biosimilar CT-P13
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both originator infliximab and biosimilar CT-P13
Number of subjects: 25
Study: 26434404

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/day
Number of subjects: 9991

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg/day
Number of subjects: 9991
Study: 25684963

Group type: EXPERIMENTAL
Intervention: PEG + M
Number of subjects: 200
Study: 23790235

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155-195 U)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 904
Study: 20226302

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg, 10 mg, 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg, 10 mg, 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Levocetirizine 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Desloratadine 20 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Increasing antihistamine doses
Number of subjects: 80
Study: 19083400

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (900 mL/d for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo pure water (900 mL/d for 8 weeks)
Number of subjects: 36
Study: 16650535

Group type: EXPERIMENTAL
Intervention: Endoscopic combination therapy (n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Diluted epinephrine injection alone (n = 53)
Number of subjects: 105
Study: 12934311

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10772522

Group type: EXPERIMENTAL
Intervention: Radially expanding needle system with blunt dilator
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sharp trocars
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Blunt dilator/cannula treatment
Number of subjects: 87
Study: 8646654

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 336
Study: 1334825

Group type: EXPERIMENTAL
Intervention: 125I‐labeled soluble insulin
Number of subjects: 12
Study: 6391441

Group type: EXPERIMENTAL
Intervention: 3% guanethidine‐0.5% epinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% guanethidine‐0.2% epinephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 40
Study: 31607641

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (overall)
Number of subjects: 61
Study: 31072274

Group type: EXPERIMENTAL
Intervention: Mini-sling surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transobturator tape
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 28387882

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid-Collagenase applied once a day
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (vehicle preparation)
Number of subjects: 113
Study: 25822306

Group type: EXPERIMENTAL
Intervention: 8% strontium dentifrice
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 8% arginine dentifrice
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (1,450 ppm NaF or water)
Number of subjects: 28
Study: 23463411

Group type: EXPERIMENTAL
Intervention: FloSeal® (FS)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Bipolar electrocautery (EK)
Number of subjects: 181
Study: 21165694

Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 0

Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 0
Study: 19661070

Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 149
Study: 17118648

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 1046

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Presence of necrosis
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Histopathological evaluation
Number of subjects: 1046
Study: 14728632

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg daily for 36 weeks)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 11210070

Group type: EXPERIMENTAL
Intervention: Open flap debridement with enamel matrix derivative (EMD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 23
Study: 9621836

Group type: EXPERIMENTAL
Intervention: Levels of processing (LOP) and selective attention during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed study condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shallow processing at test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention lag
Number of subjects: 0
Study: 7942728

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate elixir (400 mg/5 ml per os every 8 h for three doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy (no drug intervention)
Number of subjects: 20
Study: 3069774

Group type: EXPERIMENTAL
Intervention: Intravesically administered Cetiprin (emepronium bromide)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31525271

Group type: EXPERIMENTAL
Intervention: Tissue press method
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 21
Study: 31261779

Group type: EXPERIMENTAL
Intervention: Children who were underweight, wasted, or in anthropometric failure
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Overweight/obese children
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: No anthropometric status indicator
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: No demographic or socio-economic factor
Number of subjects: 893
Study: 28866988

Group type: EXPERIMENTAL
Intervention: CIRCuiTS plus treatment‐as‐usual (TAU)
Number of subjects: 93

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 93
Study: 24534756

Group type: EXPERIMENTAL
Intervention: MOR103 1.0 mg/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MOR103 1.5 mg/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: MOR103 0.3 mg/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 23406479

Group type: EXPERIMENTAL
Intervention: Directly observed HAART delivered in methadone maintenance clinics
Number of subjects: 15
Study: 21494285

Group type: EXPERIMENTAL
Intervention: Off axis retinoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: On axis retinoscopy
Number of subjects: 40
Study: 19025276

Group type: EXPERIMENTAL
Intervention: Tailored Web‐assisted tobacco intervention (Smoking Zine program)
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Interactive control condition task
Number of subjects: 1402
Study: 16870009

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food intake (measured through dietary records and urine samples)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination of fruits and/or fruit juices
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Black tea and wine consumption
Number of subjects: 53
Study: 14673606

Group type: EXPERIMENTAL
Intervention: Standardized omnivorous diet (OD) for 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian diet (VD) for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Self-selected meat-containing diet (SD) for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Western-type diet (WD) for 5 days
Number of subjects: 10
Study: 11002857

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9350924

Group type: EXPERIMENTAL
Intervention: Thallium scintigraphy after 6 months of therapy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography after 6 months of therapy
Number of subjects: 328
Study: 8250310

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 1 mg/mL of meperidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine without opioid (control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 3 micrograms/mL of fentanyl
Number of subjects: 48
Study: 2870728

Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 29362903

Group type: EXPERIMENTAL
Intervention: RTXM83-CHOP
Number of subjects: 251

Group type: COMPARATOR
Intervention: rituximab-CHOP
Number of subjects: 251
Study: 26202528

Group type: EXPERIMENTAL
Intervention: Type I BAV (right-left coronary cusp fusion)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Type I BAV
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (1000 patients with normal tricuspid aortic valve)
Number of subjects: 67
Study: 25122601

Group type: EXPERIMENTAL
Intervention: Standard-length electrode array (26.4 mm)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Medium-length electrode array (20.9 mm)
Number of subjects: 13
Study: 22634757

Group type: EXPERIMENTAL
Intervention: Fast reaching movement
Number of subjects: 11

Group type: COMPARATOR
Intervention: Slow reaching movement
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal reaching movement
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Reaching movement (general)
Number of subjects: 11
Study: 20431041

Group type: EXPERIMENTAL
Intervention: Octreotide LAR depot (up to 40 mg every 28+/‐5 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 42
Study: 18989221

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (15 sessions, individually delivered)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 616
Study: 16169793

Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization of albuterol labeled with Tc-99m DTPA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air-driven nebulization of albuterol labeled with Tc-99m DTPA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air-driven nebulization
Number of subjects: 12
Study: 12499817

Group type: EXPERIMENTAL
Intervention: Large volume paracentesis (LVP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General management
Number of subjects: 40
Study: 10071149

Group type: EXPERIMENTAL
Intervention: Systemic prednisolone treatment (group B)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 22
Study: 7768760

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 3.25 g single dose
Number of subjects: 666

Group type: COMPARATOR
Intervention: Co-trimoxazole 960 mg bd for 7 days
Number of subjects: 666
Study: 1983433

Group type: EXPERIMENTAL
Intervention: Cloxazolam (4 mg/day)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Bromazepam (12 mg/day)
Number of subjects: 837
Study: 622534

Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Whole virus vaccine (control)
Number of subjects: 50
Study: 31078511

Group type: EXPERIMENTAL
Intervention: Semi-automated CT software (QFAT 2.0, Cedars Sinai-Medical Center)
Number of subjects: 45
Study: 31729959

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFM) program, commenced pre-operatively and continued for 12 weeks post-RP
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group performing low-volume rehabilitation, commenced 5 weeks prior to surgery and continued for 12 weeks post-RP
Number of subjects: 97
Study: 26691729

Group type: EXPERIMENTAL
Intervention: Multivessel coronary artery disease
Number of subjects: 738

Group type: COMPARATOR
Intervention: Single-vessel disease
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Angiographic and electrocardiographic reperfusion success
Number of subjects: 738
Study: 24748551

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 60
Study: 23502991

Group type: EXPERIMENTAL
Intervention: landiolol
Number of subjects: 200

Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 200
Study: 21254007

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 57
Study: 19217738

Group type: EXPERIMENTAL
Intervention: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of losartan and losartan acid
Number of subjects: 0
Study: 17420345

Group type: EXPERIMENTAL
Intervention: Low-dose folic acid (400 microg/d)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-dose folic acid (5 mg/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15188836

Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg orally administered immediately post-delivery
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Placebo administered immediately post-delivery
Number of subjects: 1600
Study: 12748111

Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy (4 mL intradiscal and 8 mL periganglionic injection at 27 micro g/mL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combined oxygen-ozone therapy with corticosteroid and anesthetic injection
Number of subjects: 600
Study: 10200751

Group type: EXPERIMENTAL
Intervention: DHEA (maximum dose = 90 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 22
Study: 7540062

Group type: EXPERIMENTAL
Intervention: GM-CSF (250 micrograms/m2/d x 14 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: GM-CSF followed by G-CSF (5 micrograms/kg/d x 7 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 47

Group type: COMPARATOR
Intervention: GM-CSF followed by G-CSF
Number of subjects: 47
Study: 2183866

Group type: EXPERIMENTAL
Intervention: Paracetamol (4.0 g daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 385850

Group type: EXPERIMENTAL
Intervention: Sealed cavities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open lesions
Number of subjects: 0
Study: 31848857

Group type: EXPERIMENTAL
Intervention: Community Health Workers (CHWs) intervention for diabetes prevention
Number of subjects: 54
Study: 31566031

Group type: EXPERIMENTAL
Intervention: Wearable EEG headband for guided meditation
Number of subjects: 30

Group type: COMPARATOR
Intervention: CD-based stress-reduction education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 30
Study: 28419095

Group type: EXPERIMENTAL
Intervention: HRV (Rotarix) vaccination program
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard infant vaccines without HRV
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HRV vaccination program
Number of subjects: 142
Study: 24265118

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57
Study: 24011514

Group type: EXPERIMENTAL
Intervention: NCB-02 (curcumin) enema plus oral 5-ASA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo enema plus oral 5-ASA
Number of subjects: 45
Study: 22529754

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral methods for controlled eating
Number of subjects: 430

Group type: COMPARATOR
Intervention: Standard nutrition education
Number of subjects: 430
Study: 19183561

Group type: EXPERIMENTAL
Intervention: Linguistic cues (color words: 'red', 'green', 'blue', 'yellow' and location words: 'up', 'down', 'left', 'right')
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congruent trials
Number of subjects: 0
Study: 17305732

Group type: EXPERIMENTAL
Intervention: Vitrax
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celoftal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 60
Study: 15105390

Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer) with ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: eSET (elective single embryo transfer)
Number of subjects: 468

Group type: COMPARATOR
Intervention: ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 468

Group type: COMPARATOR
Intervention: IVF (In Vitro Fertilization)
Number of subjects: 468

Group type: COMPARATOR
Intervention: IVF cycles
Number of subjects: 468
Study: 11205180

Group type: EXPERIMENTAL
Intervention: Rapid-screening assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional procedure
Number of subjects: 0
Study: 9602258

Group type: EXPERIMENTAL
Intervention: 5000 IU rhEPO daily s.c.
Number of subjects: 227